Table 1.
Baseline characteristics of the study population
| Study ID | Device | Number of patients | Age, y | Female, n (%) | CHF, n (%) | LVEF | HTN | DM, n (%) | Stroke, n (%) | CHADS-VASC | HAS-BLED |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Paitazoglou et al. | W 2.5 | 1025 | 73.4 (8.8) | 408 (40.1) | 349 (34.1) | NA | 885 (86.6) | 304 (29.7) | 199 (19) | 4.5 (1.6) | 2.3 (1.2) |
| W-FLX | 164 | 73.7 (8.3) | 66 (40) | 54 (32.3) | NA | 147 (89.6) | 58 (35.3) | 56 (34.1) | 4.6 (1.4) | 3.2 (0.8) | |
| Vizzari et al. | W 2.5 | 100 | 77.8 (5.93) | NA | NA | NA | NA | NA | NA | NA | NA |
| W-FLX | 200 | 77 (7.18) | 65 (32.5) | 109 (54.5) | 47 (11.3) | 186 (93) | 83 (41.5) | 58 (29) | 5 (1.4) | 4 (1.01) | |
| Price et al. | W 2.5 | 48999 | 76.2 (7.7) | 20191 (41.2) | 18691 (38.1) | 54 (10.1) | 44981 (91.6) | 17439 (35.5) | 10887 (22.2) | 4.8 (1.5) | 2.9 (1.1) |
| W-FLX | 27455 | 76.2 (7.7) | 11228 (40.9) | 10620 (38.7) | 54 (10.1) | 25125 (91.6) | 9799 (35.7) | 6005 (21.9) | 4.8 (1.5) | 2.8 (1.1) | |
| Fukuda et al. | W 2.5 | 49 | 76.4 (7.4) | 13 (26) | 28 (57) | 56.6 (12.2) | 40 (82) | 17 (35) | 20 (41) | 4.9 (1.6) | 3.2 (1) |
| W-FLX | 44 | 80.8 (6.6) | 17 (39) | 28 (64) | 61.4 (14.6) | 35 (80) | 11 (25) | 15 (34) | 4.9 (1.4) | 2.8 (0.8) | |
| Galea et al. | W 2.5 | 71 | 77.1 (7.3) | 20 (28.2) | 12 (16.9) | NA | 61 (85.9) | 17 (23.9) | 20 (28.2) | 4 | 3 |
| W-FLX | 73 | 76.5 (8.4) | 23 (31.5) | 14 (19.2) | NA | 60 (82.2) | 28 (38.4) | 22 (30.1) | 4 | 3 |
CHF: Congestive Heart Failure; LVEF: Left Ventricular Ejection Fraction; HTN: Hypertension; DM: Diabetes Mellitus; W-FLX: Watchman FLX; W 2.5: Watchman 2.5.